"There are actually more patients in Japan that have this disease than there are in all of the United States. So it's a very substantial market as well."
"The ENCORE Phase 3b trial, which announced positive results on March 23, 2026, tested ARIKAYCE as a first-line combination therapy alongside standard antibiotics."
"Japan delivered 40% growth in 2025 compared to 2024 and contributed more than a quarter of ARIKAYCE's global revenues."
"If the label expands to include first-line treatment, the total addressable market grows from 30,000 to more than 200,000 patients."
Insmed's ARIKAYCE therapy targets MAC lung disease, with a current market of 30,000 patients. Positive results from the ENCORE Phase 3b trial could expand this to over 200,000 patients. Japan's market is already thriving, showing 40% growth in 2025 and contributing significantly to global revenues. The company plans to file for label expansion with the FDA and in Japan in 2026, with full commercial impact expected in 2027. Japan's growth rates outpace those of the U.S., indicating a substantial opportunity.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]